Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Assess Platelet Dysfunction With Verify Now Assay

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Nina D'Abreo, MD, Winthrop University Hospital
ClinicalTrials.gov Identifier:
NCT01167218
First received: July 19, 2010
Last updated: August 8, 2012
Last verified: August 2012

July 19, 2010
August 8, 2012
December 2009
February 2012   (final data collection date for primary outcome measure)
platelet aggregation defects [ Time Frame: one year ] [ Designated as safety issue: No ]
to assess platelet aggregation defects
to assess coronary plaque level [ Time Frame: 5 years after radiation tx ] [ Designated as safety issue: No ]
to compare plaque burden in coronary arteries in patietns who received radiotherapy for left versus right breast cancer
Complete list of historical versions of study NCT01167218 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study to Assess Platelet Dysfunction With Verify Now Assay
"In-vitro Characterization of Platelet Dysfunction in Common Hematological Disorders Using the Verify Now Assay"

The purpose of this study is to conduct a Verify now assay to detect platelet aggregation defects in patients with Myelodysplastic syndrome(MDS), immune thrombocytopenia purpura (ITP) and myeloproliferative disorders (MPD).

Verify Now is a rapid, simple, point-of service assay to measure platelet aggregation. The verify now assay is designed to assess platelet function based on the ability of activated platelets to bind fibrinogen. It is hoped that this study will detect the subtle platelet functional abnormalities in patients with hematological disorders.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

patients with platelet defects

Platelet Aggregation Defects
Not Provided
verify now assay
subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
79
February 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria

- Patients with common blood disorders such as immune thrombocytopenia purpura(ITP) myelodysplastic syndrome MDS)and myeloproliferative disorders (MPV)

Exclusion Criteria

- Patients with normal platelet counts

Both
18 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01167218
09318
No
Nina D'Abreo, MD, Winthrop University Hospital
Nina D'Abreo, MD
Not Provided
Principal Investigator: Nina D'abreo, MD Winthrop University Hospital
Winthrop University Hospital
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP